BacterOMIC

System Overview

• BactrOMIC is a phenotypic AST platform designed to rapidly and accurately determine antimicrobial susceptibility via actual bacterial growth responses under antibiotic exposure.
  
  

• Produces both quantitative MIC values (Minimum Inhibitory Concentration) and S/I/R categorizations, following CLSI/EUCAST guidelines.
  
  

Performance & Turnaround

• Time to result: Phenotypic AST typically takes 18–24 hours via traditional methods
  
  

• BactrOMIC acceleration: While exact numbers for BactrOMIC aren't accessible, rapid systems often deliver results in 4–8 hours, with microfluidic platforms achieving 1–3 hours
  
  

• This positions BactrOMIC within the short-term incubation category — <16 hours as defined by FDA guidelines for accelerated phenotypic AST systems
  
  

Please Log In to access Additional Details and documents ..

Sample Types & Throughput

• Accepted inputs: Positive blood cultures and isolated colonies from any sterile specimen (urine, sputum, wound).
  
  

• Throughput: Multiple samples can be processed in parallel; though specific device capacity isn't published, comparable systems handle 8–24 samples/run in a few hours (e.g., VITEK, Phoenix)
  
  

Accuracy & Clinical Impact

• Rapid phenotypic AST technologies consistently aim for ≥90% categorical agreement with gold-standard results
  
  

• Clinical benefits include faster targeted therapy adjustments, reduced broad-spectrum antibiotic usage, and better antimicrobial stewardship
  
  

Advantages

• True phenotypic testing: Measures growth inhibition, capturing resistance mechanisms that genetics alone may miss.
  
  

• Rapid: Likely supports same-day decision-making, critical for sepsis or severe infections.
  
  

• Automated: Reduces manual steps, minimizes errors, and supports seamless LIS/HIS integration.
  
  

Clinically relevant data: Includes actual MICs, helping tailor appropriate antibiotic dosages.